The Max Foundation, the ABC Global Alliance, the American Society of Clinical Pathology, Cepheid, and Novartis AG are joining and committing resources to improve outcomes for people living with HR+/HER2- advanced breast care in low- and middle-income countries.
Researchers at UT Southwestern reported in the journal Nature Cancer that Talzenna (talazoparib) successfully shrank the tumors of breast cancer patients with mutations in the PALB2 gene.
Through a genomic screening method known as CRISPR/CAS9 screening, Massey scientists—led by Anthony Faber and Jennifer Koblinski—identified a specific enzyme called UBA1 that revealed itself as an ideal therapeutic target in triple negative breast cancer. Using a novel UBA-inhibiting drug called TAK-243, they blocked the cellular function of UBA1 and effectively killed cancer cells in patient-derived breast tumors in mice.
An analysis of data on the use of radiation therapy in a large clinical trial of patients with HR+, HER2- breast cancer who had one to three involved lymph nodes and a 21-gene recurrence score of 25 or less found that rates of locoregional recurrence of the disease were low regardless of whether a patient had received regional node irradiation. The results suggest that a randomized clinical trial is required to answer the question of whether these favorable-risk patients can safely skip RNI.
MD Anderson Cancer Center and World Health Organization formed an agreement to establish a new international collaboration concentrated on reducing the global burden of women’s cancers. The agreement builds on years of collaboration between the two institutions to further promote their shared efforts in advancing global cancer initiatives in women’s cancers, including breast and cervical cancers.
New research indicates that among individuals with breast cancer, those with a rare subtype called inflammatory breast cancer face a higher risk that their cancer will metastasize to the brain.Â
Michele Coté was named director of the Susan G. Komen Tissue Bank, the world’s only healthy breast tissue bank, at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.Â
A new subgroup analysis across the MONALEESA phase III program found that patients with visceral metastases who were treated with Kisqali (ribociclib) plus endocrine therapy in the first-line setting achieved a median OS of 62.7 months compared to 52.1 months for those treated with endocrine therapy alone.
Giving standard chemotherapy drugs in a specific sequence for some types of metastatic breast cancer can help reduce overall costs and improve the value of care while preserving quality of life, according to a study led by UNC Lineberger Comprehensive Cancer Center and UNC Gillings School of Global Public Health researchers.
FDA has issued a safety alert informing patients and providers about reports of squamous cell carcinoma and various lymphomas located in the capsule or scar tissue around breast implants. After an initial extensive review, we currently believe that the risk of SCC and other lymphomas occurring in the tissue around breast implants is rare.Â
